| Document |
Document Title |
|
WO/2009/117095A1 |
The present invention relates to amide derivatives of Formula (XIIIa) and pharmaceutical compositions thereof that modulate the activity of the PGI2 receptor. Compounds of the present invention and pharmaceutical compositions thereof are...
|
|
WO/2009/115040A1 |
Benzoylurea compounds having the structure of formula (I) and uses thereof, wherein: R1 and R2 are independently selected from H, F, Cl, Br and I; R3, R4, R5, R6 and R7 are independently selected from H, halogen, C1-C6alkyl, C1-C6alkoxyl...
|
|
WO/2009/106351A1 |
The present invention provides a compound of formula (I): wherein: R1 is a group selected from -CH2OH1-NHCOH and R2 is a hydrogen atom; or R1 together with R2 form the group -NHC(O)CH=CH-, wherein the nitrogen atom is bound to the carbon...
|
|
WO/2008/116145A3 |
Disclosed are urea and thiourea compounds and compositions that inhibit soluble epoxide hydrolase (sEH), methods for preparing the compounds and compositions, and methods for treating patients with such compounds and compositions. The co...
|
|
WO/2009/096526A1 |
Provided is a compound having a CRTH2 antagonism and being useful as a preventive and/or remedy for inflammatory diseases (for example, asthma, allergic rhinitis, allergic dermatitis, conjunctivitis, urticaria, eosinophilic bronchitis, f...
|
|
WO/2009/096505A1 |
There have been required drugs, health foods and so on whereby subjective symptoms, for example, decline in clear thinking, defocusing and decline in memory of trivial matters can be reduced and the quality of life of people having these...
|
|
WO/2009/095164A1 |
The invention relates to a method for producing urethanes by the oxidative carbonylation of amino compounds in the presence of carbon monoxide, oxygen and organic compounds carrying hydroxyl groups, characterized in that the carbonylatio...
|
|
WO/2009/034308A3 |
There is provided a process for preparing sorafenib or a salt thereof comprising the use of a compound of formula (A), wherein R' is selected from the group consisting of hydrogen, -C(O)OA, -C(O)CX3, - OH C(O)NH2, -C(O)-NHOH or (a). Ther...
|
|
WO/2009/089192A1 |
The present invention provides novel phenoxyacetic acids useful for the prevention and treatment of inflammatory disorders, including those affecting the respiratory system and skin. The compounds are of the general formula (I):
|
|
WO/2009/089541A2 |
A method for designing a molecule capable of functioning as a PEPCK inhibitor can include identifying a molecule that has a size capable of fitting into and interacting with the PEPCK binding site and at least one of the following: (a) a...
|
|
WO/2009/086429A1 |
Disclosed are amide and urea compounds and compositions that inhibit soluble epoxide hydrolase (sEH), methods for preparing the compounds and compositions, and methods for treating patients with such compounds and compositions. The compo...
|
|
WO/2009/081892A1 |
Disclosed is a compound represented by the general formula (I) below which has a strong COMT inhibitory effect, or a pharmacologically acceptable salt thereof. Also disclosed are a pharmaceutical composition containing such a compound or...
|
|
WO/2009/015485A8 |
A CPTl inhibitor compound is represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof: or a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises a compound represented by Structural ...
|
|
WO/2008/156816A3 |
The present invention is directed to aspartic protease inhibitors. The present invention is also directed to pharmaceutical compositions comprising the disclosed aspartic protease inhibitors. The present invention is further directed to ...
|
|
WO/2009/071533A1 |
The present invention relates to novel polyisocyanates containing allophanate groups and based on isophorone diisocyanate and use thereof.
|
|
WO/2009/072798A1 |
A high adhesive acrylate monomer has a specific chemistry figure. This monomer may be easily prepared in a simplified way, and various linkers may be used between L-DOPA and an acrylate group attached to a tail of L-DOPA, so molecular we...
|
|
WO/2009/069132A2 |
Compounds that are capable of inhibiting an activity of a reverse transcriptase are disclosed. Further disclosed are pharmaceutical compositions containing these compounds, and methods of inhibiting an activity of reverse transcriptase a...
|
|
WO/2009/067597A1 |
Compounds of the formula: (I) are disclosed. The compounds act as phosphodiesterase-4 modulators, and useful for treating stroke, myocardial infarct, and cardiovascular inflammatory conditions. Other embodiments are also disclosed.
|
|
WO/2009/063804A1 |
Disclosed is a process for producing N-carbamoyl-tert-leucine, which is characterized by mixing tert-leucine with an isocyanic acid compound in an amount of 0.9 to 1.1 times the amount of tert-leucine by mole, while keeping the pH value ...
|
|
WO/2009/039361A3 |
(S)-2-(3-tert-Butylureido)-3,3-dimethylbutanoic acid is conveniently prepared in a single reaction vessel from commercially available starting materials in a process that can be run on a kilogram or larger scale.
|
|
WO/2006/014405A3 |
Various sulfonamide-based compounds are able to selectively inhibit the Src family of tyrosine kinases. These compounds are useful in the treatment of various diseases including hyperproliferative diseases, hematologic diseases, osteopor...
|
|
WO/2009/053443A2 |
This invention provides new indane compounds, their use for the treatment or prevention of melatoninergic disorders and its compositions.
|
|
WO/2006/071940A3 |
Novel compounds and methods of using those compounds for the treatment of inflammatory conditions, hyperproliferative diseases, cancer, and diseases characterized by hypervascularization are provided. In a preferred embodiment, modulatio...
|
|
WO/2009/013915A8 |
An inhibitor of plasminogen activator inhibitor-1 (PAI-1). A medicinal composition having an effect of inhibiting the PAI-1 activity and being efficacious in preventing or treating various diseases for the onset of which the PAI-1 activi...
|
|
WO/2009/050041A1 |
The present invention relates to carbamoylglycine derivatives, a process for the preparation of carbamoylglycine derivatives and the use of carbamoylglycine derivatives in the preparation of enantiomerically enriched α-amino acids. Furt...
|
|
WO/2003/082205A3 |
Disclosed is a compound having the formula (I) pharmaceutically acceptable salts or solvates thereof and pharmaceutical compositions containing the same, wherein the structural variables are as defined herein. The compounds, salts and so...
|
|
WO/2009/045830A1 |
This invention relates to a novel compound which is a glycogen phosphorylase inhibitor and its use in the treatment of diabetes and other conditions associated therewith. The invention further relates to a pharmaceutical composition cont...
|
|
WO/2005/041684A3 |
The present invention relates to the discovery that certain non-naturally occurring, non-peptide arride compounds and amide derivatives, such as oxalamides, ureas, and acrylamides, are useful flavor or taste modifiers, such as a flavorin...
|
|
WO/2009/024493A3 |
The invention relates to a novel alkenyl isocyanate characterized by the chemical formula (I). Said compound is obtained by converting isophorone diisocyanate with N-(t-butyl) aminoethyl methacrylate. The novel compound is particularly s...
|
|
WO/2008/122667A3 |
The invention concerns compounds of Formula (I) or a salt, solvate or pro-drug thereof. The compounds may be used in therapy, particularly anti-cancer therapy.
|
|
WO/2009/041482A1 |
Disclosed is an acetylene compound represented by the general formula (1) below, which is useful as a raw material for fused polymers having high heat resistance. (In the formula (1), the encircled Ar represents an aryl group or a hetero...
|
|
WO/2009/034308A2 |
There is provided a process for preparing sorafenib or a salt thereof comprising the use of a compound of formula (A), wherein R' is selected from the group consisting of hydrogen, -C(O)OA, -C(O)CX3, - OH C(O)NH2, -C(O)-NHOH or (a). Ther...
|
|
WO/2009/035928A1 |
Disclosed are amide, thoiamide, urea and thiourea compounds and compositions that inhibit soluble epoxide hydrolase (sEH), methods for preparing the compounds and compositions, and methods for treating patients with such compounds and co...
|
|
WO/2009/030752A1 |
The present invention relates to compounds of formula (I) : as well as to cosmetic and pharmaceutical compositions containing such a compound.
|
|
WO/2009/030746A1 |
The present invention relates to compounds of formula (I): and to the cosmetic and pharmaceutical compositions containing such a compound.
|
|
WO/2008/156816A8 |
The present invention is directed to aspartic protease inhibitors. The present invention is also directed to pharmaceutical compositions comprising the disclosed aspartic protease inhibitors. The present invention is further directed to ...
|
|
WO/2009/001356A3 |
Novel acyl-urea containing compounds, processes of preparing same, compositions containing same and uses thereof in the treatment of neurological diseases and disorders such as epilepsy, neuropathic pain, bipolar disorder, status epilept...
|
|
WO/2009/024493A2 |
The invention relates to a novel alkenyl isocyanate characterized by the chemical formula (I). Said compound is obtained by converting isophorone diisocyanate with N-(t-butyl) aminoethyl methacrylate. The novel compound is particularly s...
|
|
WO/2009/025829A1 |
Processes for producing a suitable purity grade of L-Citrulline are disclosed. The processes can include contacting crude L-Citrulline in an aqueous solution with an adsorptive medium at a temperature above approximately 5O0C and below t...
|
|
WO/2008/139121A3 |
The invention relates to a method for the synthesis of (Z)-3-[2-butoxy-3'-(3-heptyl-1 - methyl-ureido)-biphenyl-4-yl]-2-methoxy-acrylic acid having formula (I) and to the method for the synthesis of the reaction intermediates having gene...
|
|
WO/2009/019199A1 |
The present invention relates to a new crystalline form of R-4- trimethylammonium-3-(tetradecylcarbamoyl)-amino butyrate (also named crystalline Form I of ST 1326 or teglicar), a process for its preparation and pharmaceutical composition...
|
|
WO/2009/015485A1 |
A CPTl inhibitor compound is represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof: or a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises a compound represented by Structural ...
|
|
WO/2009/013915A1 |
An inhibitor of plasminogen activator inhibitor-1 (PAI-1). A medicinal composition having an effect of inhibiting the PAI-1 activity and being efficacious in preventing or treating various diseases for the onset of which the PAI-1 activi...
|
|
WO/2009/009278A1 |
Treating pain in mammals with a compound having the formula (I) is disclosed herein.
|
|
WO/2008/135181A3 |
The present invention relates to the use of 2-aminoindanes for controlling animal pests, especially arthropods, in particular insects. The present invention relates further to specific novel 2-aminoindanes and to compositions of these pe...
|
|
WO/2009/001356A2 |
Novel acyl-urea containing compounds, processes of preparing same, compositions containing same and uses thereof in the treatment of neurological diseases and disorders such as epilepsy, neuropathic pain, bipolar disorder, status epilept...
|
|
WO/2008/156816A2 |
The present invention is directed to aspartic protease inhibitors. The present invention is also directed to pharmaceutical compositions comprising the disclosed aspartic protease inhibitors. The present invention is further directed to ...
|
|
WO/2008/113992A3 |
The invention relates to gel composition comprising a gelating agent and a solvent. The gelating agent is a compound of general formula (I): wherein: R1is hydrogen or C1-14 alkyl; R3is OH or a group; R4 is hydrogen or C1-6 alkyl, optiona...
|
|
WO2008109991A8 |
A CPT inhibitor compound is represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof: or a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises a compound represented by Structural F...
|
|
WO/2008/143070A1 |
Disclosed is a non-covalently-bound polymer which is formed by the self-assembly of an urea compound including a long-chain-alkyl urea. Specifically disclosed is a novel non-covalently-bound polymer which has a simple chemical structure ...
|
